Microtubule-damaging agents (MDA) are potent antineoplastic drugs that are widely used in clinical treatment for a variety of cancers. However, the precise mechanisms underlying MDA-induced cell death are largely unknown. Here, we report that both p53 and Bax are central participants in the MDA-mediated cell death machinery in HCT116 human colon cancer cells. MDA, including epothilone B analogue (BMS-247550) and vinblastine, induced apoptosis of Bax-positive HCT116 cells in a p53-dependent manner; p53 was required for MDAinduced Bax conformational change. In response to MDA treatment, the BH3-only proapoptotic protein PUMA was up-regulated in p53-positive but not in p53 knockout HCT116 cells. Moreover, PUMA knockout HCT116 cells were resistant to MDA-induced Bax conformational change and apoptosis. In addition, introducing p53 plasmid DNA into p53-deficient HCT116 cells restored PUMA expression and apoptotic response to MDA treatment. However, ectopic expression of the p53 point mutation L22Q/W23S, but not the proline-rich domain deletion mutants 83-393 and ⌬ProAE, could also sensitize p53 knockout HCT116 cells to MDA-induced Bax activation and apoptosis, although all mutants failed to restore PUMA expression. Together, these findings suggest that p53 acts upstream of Bax to promote MDA-mediated cell death in a proline-rich domain-dependent manner through both transcription-dependent (by up-regulating PUMA expression) and -independent mechanisms in human colon cancer HCT116 cells.
Microtubule-damaging agents (MDA), 1 including microtubule-stabilizing agents such as taxol and epothilone B and -destabilizing agents such as vinblastine and vincristine, are effective chemotherapeutic drugs against a variety of cancers (1) (2) (3) . These drugs prevent cell cycle progression beyond the G 2 /M phase and subsequently kill cancer cells by activating apoptotic signaling pathway (4 -6) . However, the precise biochemical mechanisms by which MDA induce apoptosis are not well understood.
Mitochondria play an essential role in apoptosis induction (7) . Once death signals are transduced to mitochondria, the outer membrane of mitochondria becomes permeabilized, resulting in the release of mitochondrial proteins such as cytochrome c, Smac/Diablo, AIF, Omi/HtrA2, and Endo G into the cytosol or nucleus where they are actively involved in the process of caspase activation and protein/DNA degradation (8) .
The Bcl-2 family of proteins, which consists of both anti-and pro-apoptotic molecules, controls the mitochondrial function in apoptosis (9) . The anti-apoptotic Bcl-2 family proteins such as Bcl-2 and Bcl-XL possess four conserved BH domains (BH1-4) and prevent the release of apoptogenic molecules from mitochondria. In contrast, pro-apoptotic Bcl-2 family proteins, which can be further divided into the Bax subfamily (includes Bax, Bak, and Bok multidomain proteins) or the BH3-only subfamily (such as Bid, Bim, and PUMA), induce mitochondrial outer membrane permeabilization. It is believed that the BH1-3 proteins Bax and Bak are death effectors that are absolutely required for the mitochondrial pathway of apoptosis (10, 11) . In healthy cells, Bax exists in an inactive form, mainly in the cytosol, but can be induced to undergo a conformational change and migrate to the mitochondria by apoptotic signals (12, 13) . The conformationally changed Bax protein oligomerizes on the mitochondrial outer membrane and induces cytochrome c release (14) . The antiapoptotic Bcl-2 family proteins prevent Bax conformational change, whereas various BH3-only proteins induce it in response to apoptotic stimuli (15) .
The p53 tumor suppressor protein, which is stabilized and activated by a variety of genotoxic and non-genotoxic stress, plays a central role in the chemosensitivity and radiosensitivity of cancer cells by inducing cell cycle arrest and apoptosis (16 -18) . It has been shown that p53 triggers apoptosis by inducing mitochondrial outer membrane permeabilization through transcription-dependent and -independent mechanisms (19) . Many of the proapoptotic Bcl-2 family members such as Bax, PUMA, Noxa, and Bid have been reported to be transcriptional targets of p53 (20 -24) . In contrast, it has been demonstrated recently that upon DNA damage p53 translocates to mitochondria where it directly binds to Bcl-XL or Bak and induces Bax/Bak activation and cytochrome c release (25) (26) (27) (28) . Moreover, transcription-independent caspase-8 activation by p53 has been proposed (29) . Since the role of p53 in apoptosis induction varies between cell types and death signals, the functional importance of p53 in MDA-induced apoptosis of human cancer cells remains controversial (30 -35) .
To gain further insights into the molecular mechanisms underlying MDA-induced apoptosis, we used HCT116 cells in which the p53 or bax gene is disrupted by homologous recom-bination (36, 37) . We found that p53 regulates the death effector Bax activation by inducing the BH3-only protein PUMA in response to MDA. In addition, MDA treatment results in p53 translocation to the mitochondrion, which correlates with induction of Bax activation through a transcription-independent mechanism.
EXPERIMENTAL PROCEDURES
Materials-Epothilone B analogue (BMS-247550) was kindly provided by Bristol-Myers Squibb Co. Vinblastine and anti-actin monoclonal antibody were purchased from Sigma. Anti-p53 monoclonal antibody (DO-1) and anti-p21 polyclonal rabbit antiserum were purchased from Santa Cruz Biotechnology. Anti-p53 polyclonal antibody (CM1) was purchased from Novocastra Laboratories. Anti-p53 C-terminal antibody Pab421 was produced using a hybridoma cell line from Dr. Arnold Levine. Bak and XIAP polyclonal antibodies were purchased from Pharmingen and Alexis, respectively. Antibodies against Bax, Bcl-2, Bcl-XL, Bid, Bim, COX IV (cytochrome c oxidase complex IV), and tubulin were described previously (5, 38) . Anti-PUMA␣ polyclonal antibody (39) was kindly provided from Dr. Lin Zhang (University of Pittsburgh).
Cell Culture and Transfection-HCT116 cells were maintained in McCoy's 5A medium supplemented with 10% fetal bovine serum. To establish various p53 stable transfection clones, p53 knockout HCT116 cells in 60-mm plates were co-transfected with 4.5 g of the p53 expression plasmid pSTAR-p53, pRC/CMV-p53 (L22Q/W23S) (40), pCMV-neoBam-p53 (83-393) or pRC/CMV-p53⌬ProAE (41) together with 0.5 g of pBabe-puro empty vector by LipofectAMINE reagent (Invitrogen) according to the manufacturer's recommendation. After 24 h, the cells were spread into 16 100-mm plates and selected by 0.5 g/ml puromycin for ϳ2 weeks. Puromycin-resistant clones were isolated and screened by immunoblot analysis with p53 antibodies.
Apoptosis and Bax Conformation Assays-DNA fragmentation was determined as described previously (42) . Caspase-3 like activity was measured using the caspase-3 fluorometric assay kit (Sigma) according to the manufacturer's protocol. Bax conformational change was detected by immunoprecipitation with anti-Bax 6A7 monoclonal antibody as described (13) .
Mitochondria Isolation-HCT116 cells were suspended in 5 volumes of mitochondrial buffer (210 mM mannitol, 70 mM sucrose, 10 mM Hepes (pH 7.5), 1 mM EDTA) and homogenized with a Dounce homogenizer. The homogenate was centrifuged at 1,000 ϫ g for 10 min, and the resulting supernatant was further centrifuged at 10,000 ϫ g for 10 min. The pellet was resuspended in 400 l of mitochondrial centrifuge buffer (MCB; 300 mM mannitol, 10 mM Hepes (pH 7.5), 1 mM EDTA) and layered over discontinuous sucrose gradient formed by 1.2 and 1.6 M sucrose in 10 mM KH 2 PO 4 , 0.1% bovine serum albumin, pH 7.5. The samples were centrifuged at 100,000 ϫ g for 1 h at 4°C. Mitochondria were recovered from the interface of the two layers, washed with MCB twice, and resuspended in Chaps lysis buffer (13). 
RESULTS
To evaluate the role of p53 and Bax in MDA-mediated cytotoxicity, we treated p53 or Bax knockout HCT116 cells (37, 43) versus their parental control cells with EpoB, which induces tubulin polymerization and stabilizes microtubules, or VBL, which destabilizes microtubules for different periods or various concentrations. Cell viability was assessed by trypan blue dye exclusion assay. As shown in Fig. 1 , A and B, both EpoB and VBL could induce cell death of parental HCT116 cells in a doseand time-dependent manner. However, knockout of either p53 or Bax significantly reduced the sensitivity of HCT116 cells to death induced by these microtubule-damaging drugs. To confirm whether MDA cause cell death by induction of apoptosis, DNA ladder formation and caspase-3 activity were examined. After 12 h of treatment with 100 nM EpoB or 20 nM VBL, most of the cells stopped cell cycle at the G 2 /M phase (data not shown) followed by caspase-3 activation (Fig. 1D ) and DNA fragmentation (Fig. 1C) . However, the onset of caspase-3 activation and DNA ladder formation was obviously delayed in p53 or Bax-deficient cells (Fig. 1, C and D) , although they behaved in the G 2 /M arrest similar to their parental cells in response to MDA (data not shown). These results clearly indicate that the loss of p53 or Bax confers resistance of HCT116 cells to apoptosis induced by both microtubule-stabilizing and -destabilizing agents.
To further confirm the role of p53 in MDA-induced apoptosis, we restored p53 expression in p53-deficient HCT116 cells with a p53 expression plasmid (Fig. 2) . Several independent clones with various p53 protein levels were obtained and used to determine the functional importance of the p53 protein expression in MDA-mediated cytotoxicity. As shown in Fig. 2A , EpoB treatment resulted in stabilization and accumulation of both endogenous and exogenous p53 protein. In correlation with p53 accumulation, the p21 protein was up-regulated by EpoB, whereas the Bax protein level did not change ( Fig. 2A) . Moreover, restoration of p53 sensitized the p53 knockout HCT116 cells to apoptosis induced by EpoB or VBL (Fig. 2, B and C) . These data clearly indicate that p53 contributes to MDA-induced apoptosis of HCT116 cells. In addition, it should be noted that clone 11, which lacks both p53 and Bax, displayed reduced apoptotic cell death comparable to that in the p53 or Bax knockout cells (Fig. 2, B and C) , indicating that p53 functions upstream of Bax in controlling MDA-mediated apoptosis.
It is well accepted that p53 induces Bax expression in response to a wide variety of stress, but the protein level of Bax was not significantly altered in MDA-treated HCT116 cells (Figs. 2-4) . We have previously reported that EpoB induces Bax conformational change in human breast cancer MDA-MB-468 cells (5) . To determine whether p53 is required for MDA to induce Bax activation, p53 knockout or parental HCT116 cells were treated with EpoB or VBL and subjected to immunoprecipitation analysis with anti-Bax 6A7 antibody, which specifically recognizes the conformationally changed Bax protein (13, 44) . As expected, MDA induced Bax conformational change in p53-positive but not p53-deficient cells (Fig. 2D) . However, ectopic expression of p53 restored the sensitivity of p53 knockout HCT116 cells to MDA-induced Bax conformational change (Fig. 2E) . These results strongly suggest that p53 is critical for Bax activation and apoptosis induced by MDA.
It has been reported that antiapoptotic Bcl-2 family proteins prevent Bax conformational change, whereas proapoptotic BH3-only proteins promote it (9) . Hence, we examined the expression of Bcl-2 family proteins, including Bcl-2, Bcl-XL, Bax, Bak, PUMA, Bid, Bad, and Bim, in HCT116 or cells defective in p53 or Bax after EpoB or VBL treatment for various periods of time by immunoblot analysis. We observed that the BH3-only protein PUMA was up-regulated by MDA in parental and Bax knockout cells but not in p53-deficient HCT116 cells (Fig. 3A) , whereas the expression of Bim, Bid, Bad, Bax, Bak, Bcl-2 and Bcl-XL did not change (not shown). Moreover, the p53-dependent PUMA expression in response to MDA was confirmed in p53-restored HCT116 clones (Fig. 3B) . Mitochondrial translocation of BH3-only proteins has been suggested as a critical step in Bax activation during apoptosis (14, 45) . Furthermore, p53 has been reported to translocate to mitochondria after DNA damage and associate with Bcl-XL, resulting in the release of cytochrome c from mitochondria (25) . Thus, we performed subcellular fractionation experiments to determine the mitochondrial translocation of several proapoptotic Bcl-2 family proteins as well as p53 in HCT116 cells after EpoB or VBL treatment (Fig. 3C) . Along with the induction of PUMA expression by MDA, the portion of mitochondria-associated PUMA and Bax increased, whereas the mitochondrial localization of Bim and Bid was not altered during MDA treatment (Fig 3C) . These results suggested that PUMA is a potential initiator of MDA-induced Bax activation and apoptosis. In addition, a detectable portion of p53 also translocated to mitochondria after MDA treatment (Fig. 3C) , suggesting that p53 may directly impact on mitochondria during MDA-induced apoptosis.
To explore the role of PUMA in MDA-induced apoptosis and Bax conformational change, we next utilized HCT116 cells lacking the PUMA gene (39) . PUMAϪ/Ϫ and PUMAϩ/ϩ HCT116 cells were treated with EpoB or VBL for the indicated times and subjected to analyses of cell viability (Fig. 4C ), caspase-3 activity (Fig. 4B) , and Bax conformational change (Fig. 4D) . The deficiency of MDA-induced PUMA expression in PUMA knockout HCT116 cells was confirmed by immunoblot analysis (Fig. 4A) . As expected, PUMA-deficient cells exhibited resistance to cell death and caspase-3 activation induced by EpoB or VBL (Fig. 4, B and C) . Concomitantly, MDA-induced Bax conformational change was inhibited in PUMA-deficient cells compared with parental control HCT116 cells (Fig. 4D) . These results clearly indicated that PUMA is important for p53-mediated Bax activation and apoptosis in response to MDA.
Finally, we examined the role of p53 in MDA-induced apoptosis by transfection of p53-deficient HCT116 cells with p53 mutants lacking transcriptional activity. We utilized two kinds of p53 mutant: L22Q/W23S, which contains two point mutations in the transactivation domain, and the 83-393 deletion mutant, which lacks both the transactivation and proline-rich domains but contains the DNA binding domain required for p53 association with Bcl-XL (25, 46) . The stable transfectants were exposed to either EpoB or VBL and subjected to caspase-3 assay (Fig. 5A ) and DNA fragmentation analysis (Fig. 5B) . Ectopic expression of the L22Q/W23S mutant sensitized p53-deficient cells to MDA-induced caspase-3 activation and DNA fragmentation, whereas the deletion mutant 83-393 did not (Fig. 5, A and B) . In agreement with these results, Bax activation (6A7 positive) occurred in cells expressing p53 mutant L22Q/W23S but not 83-393 after EpoB or VBL treatment (Fig.  5C ). However, neither L22Q/W23S nor 83-393 induced PUMA expression in response to EpoB or VBL (Fig. 5D) , and both mutants could be detected in the mitochondrial fraction (not shown).
In addition, we examined another p53 mutant, ⌬ProAE, which lacks the entire proline-rich domain (amino acids 62-91) but retains the transactivation domain (41) , to further separate transcription dependent from independent effects of p53 on MDA-induced apoptosis. The p53Ϫ/Ϫ HCT116 cells were transfected with ⌬ProAE-producing plasmid DNA, and several independent clones were obtained and subjected to SDS-PAGE/ immunoblot (Fig. 6A ) and caspase-3 activity (Fig. 6B) analyses after EpoB or VBL treatment. Surprisingly, the ⌬ProAE mutant failed to induce PUMA expression (Fig. 6A ) and caspase-3 activation (Fig. 6B ) in p53Ϫ/Ϫ HCT116 cells in response to MDA. However, ⌬ProAE activated the p53 target gene, p21, in response to DNA damage (Fig. 6C) , consistent with the previous report (41) . Similar to MDA, VP-16 could induce PUMA in HCT116 cells with wild type (ϩ/ϩ) but not proline-rich domain deletion p53 (Fig. 6C) , indicating that the proline-rich domain of p53 is required for activation of the PUMA gene. Since p53 has recently been shown to interact directly with Bcl-XL (25, 27), we examined the interaction between Bcl-XL and p53 by co-immunoprecipitation to determine whether p53 binding to Bcl-XL is associated with its death-inducing activity. Unexpectedly, not only the wild type p53 but also the mutants L22Q/W23S, 83-393, and ⌬ProAE were co-immunoprecipitated with Myc-tagged Bcl-XL (Fig. 6D ) regardless of their ability to induce apoptosis. It should be noted, however, that all of these p53 mutants retain the potential Bcl-XL-binding sites (25) .
Taken together, these findings suggest that mutant p53 contributes to MDA-induced Bax activation and apoptosis as well, which probably requires both the proline-rich and Bcl-XLbinding domains.
DISCUSSION
Previous reports (30 -35) argue that the functional importance of p53 in MDA-mediated cell death machinery is depend- ent on cell type and/or concentration used. The results described in the present study show that p53 is important for MDA-induced apoptosis in human colon cancer HCT116 cells. p53 induces PUMA expression, which triggers Bax activation and apoptosis, in response to MDA. Although the majority of tumor cells have p53 mutations, MDA is widely effective against a variety of cancers. Therefore, it is possible that as tumors progress, the functional p53 gene is mutated and the loss of p53 function leads to the activation of alternative cell death pathways independent of p53 transactivity in response to MDA. Indeed, we demonstrated that p53 could contribute to MDA-mediated cytotoxicity in a transcription-independent manner as well.
The death effector Bax is a transcriptional target of p53 and plays an essential role in the mitochondrial pathway of apoptosis. In the absence of death signals, the Bax protein exists in an inactive form, but it becomes activated by a conformational change during apoptosis. Although Bax expression was not up-regulated by EpoB or VBL in HCT116 cells, our results clearly demonstrate that MDA-induced Bax conformational change depends on the presence of p53. The mechanism of how the Bax conformation is controlled in cells remains unclear, but the involvement of the BH3-only proteins has been proposed (9) .
The BH3-only protein Bim, especially the BimEL and BimL isoforms, has been reported to be sequestered on microtubules in healthy cells and to translocate to mitochondria by apoptotic stimulation (47) . It has been shown that Bim can induce Bax conformational change (38) and is important for microtubule damage-induced apoptosis (48) . In human breast cancer cells, paclitaxel treatment up-regulates Bim expression through activation of the transcription factor FoxO, which contributes to paclitaxel-induced apoptosis (49) . However, our studies indicated that neither Bim localization nor expression was altered by EpoB or VBL in HCT116 cells, suggesting that Bim may not be the primary initiator of MDA-mediated apoptosis in this colon cancer cell line. Bid is another BH3-only protein reported to be up-regulated by p53 (24) . Bid is activated by caspase-8 or granzyme B cleavage and the truncated tBid can activate Bax on mitochondria (50 -52) . Our results showing that damaging the microtubule with EpoB or VBL induces neither Bid expression nor Bid cleavage, however, suggest that Bid is also not the primary target of MDA in HCT116 cells.
PUMA is originally identified as a p53 target gene encoding a BH3 domain-containing polypeptide (21, 22) . Recent studies with knockout mice or human cancer cells demonstrated that PUMA is essential for p53-dependent apoptosis induced by DNA damage (39, 53, 54) . Furthermore, PUMA is also involved in p53-independent cell death (53, 54) . In the present study, we have further demonstrated that PUMA plays an important role FIG. 6 . The proline-rich domain of p53 is required for MDA-induced PUMA expression and apoptosis. p53Ϫ/Ϫ HCT116 cells were transfected with pRC/CMV-p53⌬ProAE plasmid DNA. Three independent clones and wild type (WT) HCT116 cells were treated with 100 nM EpoB (E), 20 nM VBL (V), or dimethyl sulfoxide (DMSO, Ϫ) for 36 h and subjected to SDS-PAGE/immunoblot analysis (A) or caspase-3 activity assay (B). C, the indicated HCT116 cells were treated with 12.5 g/ml VP-16 (ϩ) or dimethyl sulfoxide (Ϫ) for 24 h and subjected to SDS-PAGE/immunoblot analysis. D, p53Ϫ/Ϫ HCT116 cells were co-transfected with the indicated p53 expression plasmids and pcDNA3-Myc-Bcl-XL or empty vector for 12 h and treated with 100 nM EpoB for an additional 24 h. The cell lysates were prepared in Nonidet P-40 lysis buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM EDTA, 1 mM 2-mercaptoethanol, 0.5% Nonidet P-40) containing protease inhibitors and subjected to immunoprecipitation (IP) with antic-Myc affinity beads (Sigma). The resulting immune complexes and total cell lysates were analyzed by immunoblotting with antibodies specific for p53 or c-Myc epitope. in MDA-induced apoptosis of p53-positive HCT116 cells. However, the extent of Bax conformational change and caspase activation induced by EpoB or VBL in PUMA-deficient HCT116 cells seems to be less than those in p53 knockout HCT116 cells. In addition, MDA could induce caspase-3 activation in HCT116 cells treated with the translation inhibitor cycloheximide (data not shown). Therefore, p53 may also contribute to Bax-dependent caspase activation through a transcription-independent pathway as reported previously (25, 55) . In fact, the levels of mitochondria-associated p53 increased in MDA-treated cells (Fig. 3C) , as previously observed in the cells treated by DNA damage (25, 26) . However, how p53 exerts its transcriptionindependent proapoptotic activity is still controversial. Mihara et al. (25) have shown that the p53 DNA-binding domain is essential for its association with Bcl-XL and death-inducing activity, whereas other reports (27, 56) have indicated that the proline-rich domain is critical for p53 to induce transcriptionindependent apoptosis. Our results obtained from three distinct p53 mutants, the L22Q/W23S point mutation and the proline-rich domain deletion mutants 83-393 and ⌬ProAE (which contain the Bcl-XL-binding sites), strongly suggested that the proline-rich region of p53 may be involved in p53-mediated transactivation-independent Bax conformational change, caspase activation, and apoptosis of HCT116 cells in response to MDA.
In summary, p53 plays a pivotal role in MDA-induced apoptosis of HCT116 cells by activating the death effector Bax through induction of the BH3-only protein PUMA expression (Fig. 7) . In addition, a transcription-independent pathway may also participate in p53-mediated Bax activation in response to MDA (Fig. 7) . Clearly, further studies are required to determine the precise molecular mechanisms underlying the regulation of p53 transactivation and transcription-independent pro-apoptotic activity by MDA.
